Novo Nordisk Symposium, with Dr Sarah Davies, Jaya Authunuri and Tessa Moore. Please double click for more information.
This is a promotional symposium for UK Healthcare professionals. organised and funded by Novo Nordisk. Novo Nordisk products will be discussed.
- Dr Sarah Davies, GPwSI in Diabetes
- Jaya Authunuri, Pharmacist and Practice Manager
- Tessa Moore, DSN
What role does an Oral GLP-1 receptor agonist▼ have in primary care.
A case based discussion.
This session is a case based discussion which addresses how to both initiate and manage adult type 2 diabetes patients who have been prescribed Rybelsus▼® (semaglutide tablets) in a primary care setting, to improve their glycaemic control[1]. Type 2 diabetes is a progressive disease, over time glycaemia increases, beta-cell function declines and complications develop. Rybelsus® (oral semaglutide) may give your patients more choice in how to manage their T2D.
[1] RYBELSUS® Summary of Product Characteristics. Bagsværd, Denmark: Novo Nordisk A/S
Learning Outcomes:
- To understand the progressive nature of T2D and the importance of glycaemic control
- To understand the considerations for when is the right time to start an oral GLP-1 RA treatment
- To explore relevant RYBELSUS® (oral semaglutide) clinical data and their implications
on adult T2D care
Please note this session is not eligible for accreditation.
Prescribing information and adverse event reporting can be found within the session and on the Novo Nordisk Exhibition stand. Prescribing information for Rybelsus can be found here.
Scan the QR code to register your consent to receive communications from Novo Nordisk. Communications may include promotional materials.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Stores. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 0232573). Calls may be monitored for training purposes.
UK21RYB00273, Date of preparation: October 2021
-(002).jpg){kind=logo}
